Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adapt, adjudicated, AgainstDiffuseAggressiveLymphoma, BackboneTreatmentsofMultiple, breakdown, bridge, cardiac, Celegene, chromosome, compelling, concert, corticospinal, CRi, Danish, Deepika, deletion, Eli, enasidenib, epilepsy, epileptic, ESMO, exploration, explore, febrile, FileNo, FN, India, isatuximab, isolate, Jazz, lift, lifted, lifting, linked, modification, MRD, narrative, neuropathy, nonhematologic, Notably, online, pain, pamolidomide, PC, PCs, perfunctory, Ph, pilocarpine, poster, preatreated, precisely, qualitative, quantitative, Radiological, reconciling, reiterated, robust, RSV, SDd, SELHEM, sequellae, signifying, Singapore, SLE, SPd, subgroup, SVd, syncytial, tAML, treatable, TreatmentofRefractoryMyeloma, true, undertaken, underway, unused, Vd, visit, warranting, washout
Filing tables
Filing exhibits
Related press release
KPTI similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-3 No. 333-201366) of Karyopharm Therapeutics Inc., |
(2) | Registration Statement (Form S-3 No. 333-214489) of Karyopharm Therapeutics Inc., |
(3) | Registration Statement (Form S-8 No. 333-194746) pertaining to the 2010 Stock Incentive Plan, 2013 Stock Incentive Plan, and 2013 Employee Stock Purchase Plan of Karyopharm Therapeutics Inc., |
(4) | Registration Statement (Form S-8 No. 333-202742) pertaining to the 2013 Stock Incentive Plan of Karyopharm Therapeutics Inc., and |
(5) | Registration Statement (Form S-8 No. 333-210221) pertaining to the 2013 Stock Incentive Plan of Karyopharm Therapeutics Inc.; |
of our report dated March 16, 2017, with respect to the consolidated financial statements of Karyopharm Therapeutics Inc. included in this Annual Report (Form 10-K) of Karyopharm Therapeutics Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP |
Boston, Massachusetts
March 16, 2017